Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Aim of this trial is to assess the pharmacokinetics and pharmacodynamics (PK/PD) of
recombinant human coagulation factor VIIa for injection (FⅦa) in patients with hemophilia.